| Literature DB >> 30343048 |
Yang Gu1, Xueqin Lv1, Yanfeng Liu1, Jianghua Li1, Guocheng Du1, Jian Chen1, Ledesma-Amaro Rodrigo2, Long Liu3.
Abstract
One of the primary goals of microbial metabolic engineering is to achieve high titer, yield and productivity (TYP) of engineered strains. This TYP index requires optimized carbon flux toward desired molecule with minimal by-product formation. De novo redesign of central carbon and redox metabolism holds great promise to alleviate pathway bottleneck and improve carbon and energy utilization efficiency. The engineered strain, with the overexpression or deletion of multiple genes, typically can't meet the TYP index, due to overflow of central carbon and redox metabolism that compromise the final yield, despite a high titer or productivity might be achieved. To solve this challenge, we reprogramed the central carbon and redox metabolism of Bacillus subtilis and achieved high TYP production of N-acetylglucosamine. Specifically, a "push-pull-promote" approach efficiently reduced the overflown acetyl-CoA flux and eliminated byproduct formation. Four synthetic NAD(P)-independent metabolic routes were introduced to rewire the redox metabolism to minimize energy loss. Implementation of these genetic strategies led us to obtain a B. subtilis strain with superior TYP index. GlcNAc titer in shake flask was increased from 6.6 g L-1 to 24.5 g L-1, the yield was improved from 0.115 to 0.468 g GlcNAc g-1 glucose, and the productivity was increased from 0.274 to 0.437 g L-1 h-1. These titer and yield are the highest levels ever reported and, the yield reached 98% of the theoretical pathway yield (0.478 g g-1 glucose). The synthetic redesign of carbon metabolism and redox metabolism represent a novel and general metabolic engineering strategy to improve the performance of microbial cell factories.Entities:
Keywords: Bacillus subtilis; Metabolic engineering; Microbial cell factories; N-acetylglucosamine; Overflow metabolism; Redox metabolism; Synthetic biology
Mesh:
Substances:
Year: 2018 PMID: 30343048 DOI: 10.1016/j.ymben.2018.10.002
Source DB: PubMed Journal: Metab Eng ISSN: 1096-7176 Impact factor: 9.783